Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Key Highlights
- ➤Autolus will present updated CARLYSLE Phase 1 data on November 10, 2026
- ➤obe-cel follow-up reaches 20 months in adults with severe refractory SLE
- ➤Adolescent CARLYSLE participants have at least three months of follow-up
- ➤Updated presentation will include safety and efficacy results for obe-cel
LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Florida. Updated data from the ongoing Phase 1 CARLYSLE trial in patients with severe refractory systemic lupus erythematosus (srSLE) will be presented in a poster on November 10.
Abstract: 2216 Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I CARLYSLE Study Session date and time: Tuesday, November 10, 2026; 10:30 AM–12:30 PM ET
Get started
Create a free account to read the full story.